Edited HSPCs rescue frataxin deficiency and inflammation-driven neurologic, cardiac and pancreatic pathology in Friedreich’s ataxia

Current therapies do not correct the underlying genetic defect. Here, we demonstrate that ex vivo CRISPR/Cas9 excision of the GAA expansion in hematopoietic stem and progenitor cells (HSPCs) provides a durable, systemic therapy for FRDA.

A single infusion of gene-edited Sca1+ HSPCs, mPPL-001, into myeloablated, humanized YG8JR mice resulted in long-term engraftment of donor-derived cells across hematopoietic and FRDA-affected tissues. mPPL-001 increased FXN expression and corrected multiple key pathogenic drivers of FRDA, including mitochondrial stress, microglial and macrophage activation, and inflammatory signaling. These coordinated effects improved motor functions, preserved cerebellar architecture, mitigated cardiac pathology and promoted survival and proliferation of insulin-producing β-cells in the pancreatic islet of Langerhans.